{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:03:33Z","timestamp":1774883013353,"version":"3.50.1"},"reference-count":52,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-QL202102-0271"],"award-info":[{"award-number":["Y-QL202102-0271"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,5,3]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian clear cell carcinoma (OCCC) has an abysmal prognosis with a median overall survival (OS) of 25.3 months because of a low response to chemotherapy. The 5-year disease-specific survival rate after recurrence is 13.2%, with more than two-thirds of the patients dying within a year. Therefore, it is urgent to explore new therapeutic options for OCCC. Based on the characteristic immune-suppressive tumour microenvironment derived from the gene expression profile of OCCC, the combination of immunoantiangiogenesis therapy might have certain efficacy in recurrent\/persistent OCCC. This trial aims to evaluate the efficacy and safety of sintilimab and bevacizumab in patients who have failed platinum-containing chemotherapy with recurrent or persistent OCCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method and analysis<\/jats:title>\n                    <jats:p>In this multicentre, single-arm, open-label, investigator-initiated clinical trial, 38 patients will be assigned to receive sintilimab 200\u2009mg plus bevacizumab 15\u2009mg\/kg every 3\u2009weeks. The eligibility criteria include histologically diagnosed patients with recurrent or persistent OCCC who have been previously treated with at least one-line platinum-containing chemotherapy; patients with Eastern Cooperative Oncology Group (ECOG) performance status 0\u20132 with an expected survival greater than 12 weeks. The exclusion criteria include patients previously treated with immune checkpoint inhibitor and patients with contraindications of bevacizumab and sintilimab. The primary endpoint is the objective response rate. The secondary endpoints are progression-free survival, time to response, duration of response, disease control rate, OS, safety and quality of life. Statistical significance was defined as p&lt;0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>\n                      This trial was approved by the Research Ethics Commission of Tongji Medical College of Huazhong University of Science and Technology (2020-S337). The protocol of this study is registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>\n                      . The trial results will be published in peer-reviewed journals and at conferences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04735861\">NCT04735861<\/jats:ext-link>\n                      ; Clinicaltrials. gov.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-058132","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T04:04:25Z","timestamp":1653451465000},"page":"e058132","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Sintilimab combined with bevacizumab in relapsed\/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial\u2014a study protocol of clinical trial"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04735861","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ruyuan","family":"Li","sequence":"first","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Song","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahao","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Jiao","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoqing","family":"Zeng","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Chi","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanchen","family":"Ma","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yabing","family":"Huo","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zikun","family":"Peng","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Wuhan Union Hospital, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shandong University Qilu Hospital, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-3423","authenticated-orcid":false,"given":"Qing-Lei","family":"Gao","sequence":"additional","affiliation":[{"name":"Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"2025121605475172000_12.5.e058132.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21559"},{"key":"2025121605475172000_12.5.e058132.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456"},{"key":"2025121605475172000_12.5.e058132.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21564"},{"key":"2025121605475172000_12.5.e058132.4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"2025121605475172000_12.5.e058132.5","unstructured":"The International Agency for Research on Cancer . Global cancer statistics, 2021. Available: https:\/\/gcoiarcfr\/ [Accessed Mar 2021]."},{"key":"2025121605475172000_12.5.e058132.6","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182540145"},{"key":"2025121605475172000_12.5.e058132.7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5"},{"key":"2025121605475172000_12.5.e058132.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.01158.x"},{"key":"2025121605475172000_12.5.e058132.9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10147-020-01625-w","article-title":"Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma","volume":"25","author":"Takahashi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"2025121605475172000_12.5.e058132.10","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.470"},{"key":"2025121605475172000_12.5.e058132.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63605-X"},{"key":"2025121605475172000_12.5.e058132.12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025121605475172000_12.5.e058132.13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3098"},{"key":"2025121605475172000_12.5.e058132.14","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.251"},{"key":"2025121605475172000_12.5.e058132.15","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw030"},{"key":"2025121605475172000_12.5.e058132.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3314"},{"key":"2025121605475172000_12.5.e058132.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397"},{"key":"2025121605475172000_12.5.e058132.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135"},{"key":"2025121605475172000_12.5.e058132.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059"},{"key":"2025121605475172000_12.5.e058132.20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2018.05.029","article-title":"A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group Study (GOG-254)","volume":"150","author":"Chan","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025121605475172000_12.5.e058132.21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2018.04.572","article-title":"Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)","volume":"150","author":"Konstantinopoulos","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2025121605475172000_12.5.e058132.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1244"},{"key":"2025121605475172000_12.5.e058132.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021121"},{"key":"2025121605475172000_12.5.e058132.24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep"},{"key":"2025121605475172000_12.5.e058132.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008433"},{"key":"2025121605475172000_12.5.e058132.26","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.228"},{"key":"2025121605475172000_12.5.e058132.27","doi-asserted-by":"publisher","DOI":"10.1038\/nature12222"},{"key":"2025121605475172000_12.5.e058132.28","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1111\/j.1349-7006.2010.01736.x","article-title":"Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling","volume":"101","author":"Matsumura","year":"2010","journal-title":"Cancer Sci"},{"key":"2025121605475172000_12.5.e058132.29","unstructured":"Sahebjam S , Forsyth PA , Tran ND . Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high grade gliomas: results from a phase 1 study. Neuro Oncol 2020."},{"key":"2025121605475172000_12.5.e058132.30","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.19.02394","article-title":"Phase Ib\/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003","volume":"38","author":"Dudek","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025121605475172000_12.5.e058132.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7"},{"key":"2025121605475172000_12.5.e058132.32","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","article-title":"Reliability and validity of the functional assessment of cancer therapy-ovarian","volume":"19","author":"Basen-Engquist","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025121605475172000_12.5.e058132.33","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-29"},{"key":"2025121605475172000_12.5.e058132.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(00)00065-4"},{"key":"2025121605475172000_12.5.e058132.35","doi-asserted-by":"publisher","DOI":"10.1249\/01.MSS.0000078924.61453.FB"},{"key":"2025121605475172000_12.5.e058132.36","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"2025121605475172000_12.5.e058132.37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1439"},{"key":"2025121605475172000_12.5.e058132.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.11.017"},{"key":"2025121605475172000_12.5.e058132.39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ygyno.2019.05.021","article-title":"Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced\/recurrent ovarian and uterine cancers","volume":"154","author":"Liu","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2025121605475172000_12.5.e058132.40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian cancer: phase 1B results from the javelin solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025121605475172000_12.5.e058132.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006"},{"key":"2025121605475172000_12.5.e058132.42","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-020-00751-3","article-title":"Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report","volume":"13","author":"Lin","year":"2020","journal-title":"J Ovarian Res"},{"key":"2025121605475172000_12.5.e058132.43","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s12094-020-02446-z","article-title":"Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?","volume":"23","author":"Gallego","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"2025121605475172000_12.5.e058132.44","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1096"},{"key":"2025121605475172000_12.5.e058132.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1956"},{"key":"2025121605475172000_12.5.e058132.46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2325"},{"key":"2025121605475172000_12.5.e058132.47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"2025121605475172000_12.5.e058132.48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1852"},{"key":"2025121605475172000_12.5.e058132.49","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724"},{"key":"2025121605475172000_12.5.e058132.50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30413-9"},{"key":"2025121605475172000_12.5.e058132.51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a multicenter phase II study of Atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or Sarcomatoid features","volume":"38","author":"McGregor","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025121605475172000_12.5.e058132.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-058132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:48:02Z","timestamp":1765892882000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-058132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,24]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bmjopen-2021-058132"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-058132","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}